DexCom stock: buy or sell?
May 14th, 2020
DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Should I buy DexCom stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, DexCom stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is DexCom stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for DXCM stock for the last 30 days.
DexCom stock analysis
After marking all time highs on Monday, DexCom slightly fell -1.02% today to $403.05.
After marking all time highs on Monday, DexCom slightly fell -1.02% today to $403.05. From a daily perspective, DXCM is in a short term uptrend after plotting its last bottom ($312.15, on April 28th) higher than the previous bottom, and its last top ($428.00, on Monday) also over the previous top. Now trading in between its last bottom and last top DXCM might consolidate in a plain range, waiting to break out over $428.00 or down under $312.15. Since last March when DXCM stock price broke up the SMA100d line, it gained $192.75 (91.65%). On Monday, DXCM hit a new all time high, pushing higher than on Friday tops. Check different trading setups that use ATHs as triggers.
DexCom topped new all time highs back again this week, setting highs to $428.00. Shares closed at $403.05 and slightly fell -0.60% during the week. Last week DXCM boosted a dazzling 15.78% in just one week. After 4 weeks soaring, this week declined a -0.72%.
Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $306.71 resistance. By mid August 2019, SMA20w and SMA40w crossed up triggering a rise of 159.30%. Since price and SMA40w lines crossed up by mid June 2019, DXCM climbed $277.07 (219.93%).
DexCom stock price history
DexCom IPO was on April 14th, 2005 at $12.08 per share1. Since then, DXCM stock surged a 3,236.50%, with a yearly average of 215.80%. If you had invested right after DXCM's IPO a $1,000 in DexCom stock in 2005, it would worth $32,365.00 today.
1: Adjusted price after possible price splits or reverse-splits.
DexCom stock historical price chart
DXCM stock reached all-time highs on Monday with a price of $428.00.
DexCom stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not detected any price target for DexCom stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareDexCom reported dazzling results for 2018-Q4 . DexCom boosted Earnings per Share (EPS) by 237.50%, beating analysts consensus of $0.16. DexCom posted $0.54.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an extraordinary growth of 43.58% to $1,031.60 M USD. When comparing 2018 vs 2017, by contrast, profit margin (that is, the net income divided by revenues) fell a -5.33% to -12.32%.
|2013||$160 M||-||$-29.80 M-18.6%||-|
|2014||$259 M||62.00%||$-22.40 M-8.6%||-24.83%|
|2015||$402 M||55.09%||$-57.60 M-14.3%||157.14%|
|2016||$573 M||42.61%||$-65.60 M-11.4%||13.89%|
|2017||$719 M||25.33%||$-50.20 M-7.0%||-23.48%|
|2018||$1,032 M||43.58%||$-127.10 M-12.3%||153.19%|
Quarterly financial resultsDexCom reported $338.00 M in sales for 2018-Q4, a 26.73% up compared to previous quarter. Reported quarter earnings marked $-179.70 M with a profit margin of -53.17%. Profit margin plummed a -70.64% compared to previous quarter when profit margin was 17.47%. When comparing revenues to same quarter last year, DexCom sales marked an exceptional gain and climbed a 52.94%. Looking back to recent quarterly results, DexCom posted 3 positive quarters in a row.
|2017-Q2||$171 M||-||$2.90 M1.7%||-|
|2017-Q3||$185 M||8.21%||$-2.00 M-1.1%||-168.97%|
|2017-Q4||$221 M||19.72%||$-9.40 M-4.3%||370.00%|
|2018-Q1||$184 M||-16.56%||$-24.20 M-13.1%||157.45%|
|2018-Q2||$243 M||31.51%||$30.20 M12.5%||-224.79%|
|2018-Q3||$267 M||9.98%||$46.60 M17.5%||54.30%|
|2018-Q4||$338 M||26.73%||$-179.70 M-53.2%||-485.62%|
|2019-Q1||$281 M||-17.01%||$-26.90 M-9.6%||-85.03%|
DexCom ownershipWhen you are planning to invest in a stock, it's worth to review its ownership structure.
DexCom shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.44% of all shares.
Bearish positions for DXCM stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$37.2 B|
|Total shares||92.3 M|
|Float shares||91.7 M|
|- Institutional holdings (%)||100.5%|
|- Insider holdings (%)||0.4%|
|Shares in short selling||0.0%|
|Thursday, May 14th, 2020|
|Day range||$396.72 - $408.71|
|Average true range||$19.77|
|50d mov avg||$294.82|
|100d mov avg||$270.70|
|200d mov avg||$222.40|
DexCom performanceTo better understand DexCom performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare DexCom performance to :
DexCom competitorsUnfortunately, we could not find any public company that could be defined as DexCom competitor. This doesn't mean DexCom does not have any competitor in the market, it's just we could not detected it.
Latest DexCom stock news
- InvestorPlaceDexCom Stock Skyrockets on Q2 Earnings BeatAugust 2, 2018